Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-25T13:36:49.771Z Has data issue: false hasContentIssue false

21 The Microbial Antibiogram as a Function of Testing Indication: Susceptibility Analysis of Escherichia coli from Symptomatic and Asymptomatic Bacteriuria Patients, 2020-2021

Published online by Cambridge University Press:  03 April 2024

Allison Chan
Affiliation:
Vanderbilt University Medical Center, Department of Pathology, Microbiology, and Immunology; Nashville, Tennessee 37232 USA
Maddie Spradley
Affiliation:
Vanderbilt University Medical Center, Department of Pathology, Microbiology, and Immunology; Nashville, Tennessee 37232 USA
Tim Williams
Affiliation:
Vanderbilt University Medical Center, Department of Pathology, Microbiology, and Immunology; Nashville, Tennessee 37232 USA
Grace Morales
Affiliation:
Vanderbilt University Medical Center, Department of Pathology, Microbiology, and Immunology; Nashville, Tennessee 37232 USA
Gerald Van Horn
Affiliation:
Vanderbilt University Medical Center, Department of Pathology, Microbiology, and Immunology; Nashville, Tennessee 37232 USA
Jonathan E. Schmitz
Affiliation:
Vanderbilt University Medical Center, Department of Pathology, Microbiology, and Immunology; Nashville, Tennessee 37232 USA Department of Urology, Vanderbilt Institute for Infection, Immunology, and Inflammation; Nashville, Tennessee 37232 USA
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

OBJECTIVES/GOALS: Antibiograms are used to guide empiric antibiotic selection. However, it is unclear if antibiotic profiles differ between symptomatic urinary tract infections (UTIs) and asymptomatic bacteriuria (ASB). We aimed to compare antibiotic susceptibility profiles of urinary E. coli isolates from patients with a symptomatic UTI to those with ASB. METHODS/STUDY POPULATION: We conducted a cohort study of 1,140 urinary E. coli isolates from unique patients that received care through Vanderbilt University Medical Center (VUMC) from Nov 2020 – Jun 2021. We included any patient that was seen at VUMC as an inpatient, outpatient or at the emergency department with ≥ 105 colony forming units/mL E. coli detected from a clinical urine specimen. Chart abstractions were performed to capture reported UTI symptoms and demographic information. Descriptive statistics were conducted to compare antibiotic susceptibility profiles (i.e., susceptible, intermediate, resistant) between symptomatic and ASB groups. The risk of detection of a multidrug-resistant organism (MDRO) (intermediate, or resistant to at least one antibiotic in three or more classes) was assessed between groups. RESULTS/ANTICIPATED RESULTS: Among 1,140, 1,018 (89%) and 122 (11%) were symptomatic and ASB, respectively. When comparing symptomatic and ASB, the median ages were 50 and 46. Groups had similar proportions of no indwelling catheter (94% v. 95%) and without diabetes (87% v. 88%). The collection setting between inpatient, emergency department, and outpatient were similar with most being outpatient (79% v. 83%). The proportion of patients who were pregnant, immuno compromised, or had a structural/functional urinary tract abnormality were higher in the symptomatic group. The proportion of isolates resistant and susceptible to tested antibiotics were similar between groups, with only ciprofloxacin showing slightly higher resistance among ASB (16% v. 25%). The risk of MDRO detection was similar between groups (RR: 0.858, 95% CI: 0.64, 1.15). DISCUSSION/SIGNIFICANCE: Antibiotic susceptibility comparison demonstrated similar profiles, which suggests antibiogram use as appropriate to guide ASB treatment. Results offer insight on whether traditional methods for assessing antibiotic susceptibility on population-levels could benefit from further refinement by patient-specific clinical parameters.

Type
Biostatistics, Epidemiology, and Research Design
Creative Commons
Creative Common License - CCCreative Common License - BYCreative Common License - NCCreative Common License - ND
This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is unaltered and is properly cited. The written permission of Cambridge University Press must be obtained for commercial re-use or in order to create a derivative work.
Copyright
© The Author(s), 2024. The Association for Clinical and Translational Science